Pe Healthcare Investors Marketing Mistakes India

Author: Abhash Kumar · Co-Founder, ICG · July 2026

ICG has conducted marketing due diligence for PE firms evaluating Indian healthcare businesses, and marketing transformation engagements for PE portfolio companies. The pattern across these engagements is consistent: PE investors are asking the wrong marketing questions.

Here are the 4 questions they typically ask, why they do not matter, and the 4 questions they should ask instead.

Question they ask #1: "What is your CPL?" Why it does not matter: CPL is the cost of an enquiry. It has no direct relationship to consultation revenue or procedure revenue. A ₹300 CPL at 25% attendance is ₹1,200 CPQL. A ₹800 CPL at 70% attendance is ₹1,143 CPQL. The ₹800 CPL account is marginally more efficient at the patient level.

Question they should ask: "What is your CPQL by specialty, and how does it compare to the ICG benchmark for this specialty and city?" This is the question that reveals actual marketing efficiency. ICG's CPQL benchmarks (15 specialties × 14 cities, Q2 2026) provide the comparison point. A portfolio company whose CPQL is 50% above the ICG benchmark for its specialty has a specific, quantifiable marketing efficiency problem.

Question they ask #2: "What percentage of leads convert to consultations?" Why it matters but is incomplete: enquiry-to-consultation conversion rate is a useful funnel metric. But it does not account for the quality of the original enquiry — a high conversion rate from a low-quality lead pool can produce acceptable consultation volume at unacceptable CPQL. And it does not account for the attendance rate — "consultation booked" is not "consultation attended."

Question they should ask: "What is your consultation attendance rate by specialty, and what percentage of consultations become procedures?" Attendance rate (35–45% for IVF; 55–65% for GP) and consultation-to-procedure conversion rate are the downstream funnel metrics that determine actual patient revenue. High enquiry volume at low attendance rate is a patient coordination problem, not a marketing problem. High attendance rate at low consultation-to-procedure conversion is a clinical conversion or pricing problem.

Question they ask #3: "What are your marketing channels?" Why it does not matter (alone): knowing that a portfolio company uses Google Ads, Meta Ads, and SEO says nothing about how efficiently it uses them, how it attributes results between them, or which channel is generating the best-quality patients.

Question they should ask: "What percentage of consultation revenue is attributable to each marketing channel, and what is the channel-level CPQL?" This is the attribution question. A portfolio company that cannot answer this does not have channel-level attribution infrastructure. The implication: their budget allocation is based on CPL (cheap-to-generate signals) rather than CPQL (attended consultation quality). The marketing spend is almost certainly misallocated.

Question they ask #4: "Are you NMC-compliant?" Why it matters but is insufficient: "yes" to this question is almost universally the answer — even from organisations with active NMC-non-compliant advertising. Most healthcare marketing teams do not know what NMC Section 6 requires in specific detail. "We are compliant" often means "we have not been complained about."

Question they should ask: "When was the last NMC Section 6 compliance review of all active advertising creative and website copy, and who conducted it?" A portfolio company that has a documented compliance review process (12-point checklist, conducted before every content publish, by a named compliance reviewer) is in a fundamentally different position from one that has "always tried to be compliant." The former has zero formal complaints risk from this source. The latter has latent exposure.

The additional question no PE investor asks but should: "What is your LLM citation rate?" With 18–22% of urban Indian patients starting healthcare research on AI tools and this figure doubling annually, a portfolio company's visibility in ChatGPT, Perplexity, and Google AI Overview is a forward-looking patient acquisition metric. A company with a 23% LLM citation rate across target queries is building a compounding organic patient acquisition asset. A company with a 4% citation rate is invisible at the first touchpoint for 20–25% of its addressable patient market.

yoda/02-aio-lab-rank-checker.png" alt="YODA AIO Lab Rank Checker — daily monitoring of AI Overview citation status for every tracked healthcare query" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

This question does not exist in any PE healthcare DD checklist ICG has reviewed. It will.

→ PE Healthcare Marketing: The Full Due Diligence Framework